Bausch + Lomb Surges on Strong Q2 2026 Performance and Optimistic Outlook

The Toronto‑listed eye‑care specialist Bausch + Lomb Corp. (TSX: BHC) rallied sharply following the release of its second‑quarter 2026 results, which demonstrated robust revenue growth, improved earnings, and a heightened guidance that underpins the company’s long‑term value proposition.

1. Consolidated Results Outpace Expectations

  • Revenue: Second‑quarter consolidated revenues reached $2.85 billion, marking a 13 % increase on a reported basis and 11 % on an organic (non‑GAAP) basis versus the same period last year.
  • Net Income: GAAP net income attributable to Bausch + Lomb rose to $258 million, an uptick that reflects disciplined cost management amid a higher top‑line.
  • Earnings per Share: GAAP earnings per diluted share attributable to Bausch + Lomb climbed to $0.68 from $0.40 in Q2 2025, a 70 % jump that underscores the company’s capacity to generate shareholder value.
  • Adjusted EBITDA: Adjusted EBITDA attributable to Bausch + Lomb (non‑GAAP) hit $1,075 million, up 28 % over the prior year period, and this trend has continued for the thirteenth consecutive quarter of year‑over‑year growth in both revenue and adjusted EBITDA.

2. Cash Generation and Working Capital Strength

  • Operating Cash Flow: The company generated $517 million in cash from operating activities, while adjusted cash flows from operations (non‑GAAP) amounted to $471 million.
  • Cash Discipline: The robust cash generation provides a buffer against market volatility and supports future capital allocation, including strategic acquisitions, share‑repurchase programmes, and potential dividend enhancements.

3. Forward Guidance and Strategic Outlook

Bausch + Lomb has lifted its full‑year 2026 guidance for revenue, adjusted EBITDA (non‑GAAP), and adjusted cash flows from operations (non‑GAAP). This upward revision reflects:

  • Continued demand for the company’s eye‑care portfolio, spanning ophthalmic pharmaceuticals, contact lenses, lens care products, and surgical devices.
  • Operational efficiencies realized through its global supply chain optimisation and cost‑control initiatives.
  • Investment in innovation, particularly in emerging therapeutic areas that could broaden the company’s market footprint.

4. Market Context and Competitive Landscape

Despite heightened competition for ophthalmic equipment—illustrated by Ferris Optical Inc.’s recent push to provide affordable used equipment—the industry remains resilient. Bausch + Lomb’s established brand reputation and comprehensive product offering position it well to capture both new‑market and replacement‑equipment demand.

5. Investor Takeaway

The convergence of higher-than‑expected earnings, disciplined cash generation, and an optimistic guidance trajectory reinforces Bausch + Lomb’s standing as a leading player in the health‑care sector. The company’s 52‑week high of $25.70 and market capitalisation of over 8 billion CAD signal a resilient valuation foundation, even as the price‑earnings ratio currently sits at a negative 26.6—an artefact of recent profitability improvements.

Bottom line: Bausch + Lomb’s Q2 performance, coupled with its forward‑looking guidance, suggests a continued upward trend in shareholder value, underscoring the company’s strategic focus on growth, operational excellence, and innovation in eye care.